This research study is evaluating an investigational medication for IgA nephropathy (IgAN) in adults. You may be able to take part in this study if you:
Study participation will last up to 110 weeks and includes up to 26 visits. This includes a 22-week treatment period followed by an 82-week follow-up period. Those who qualify will be randomly assigned (like flipping a coin) to receive either the investigational medication (called mezagitamab) or a placebo (a substance that looks like the investigational medication but contains no active ingredients), along with standard-of-care therapy. Two out of every 3 participants will receive the investigational medication, and 1 out of 3 will receive the placebo.
During the 22-week treatment period, participants will receive subcutaneous (under the skin) injections for a total of 16 doses. Participants will then enter an 82-week follow-up period.
Participation can last up to 110 weeks and includes up to 26 visits.
The investigational medication is a compound that aims to slow down the progression of IgAN by reducing how much of the defective IgA protein is produced in the body. It will be given as a subcutaneous (under the skin) injection.
Do not discontinue any medication unless you are advised to do so by the study staff or your primary care provider.
Travel-related support for this study may be available depending on country and site regulatory approvals. The investigational medication, placebo, and all study-related tests will be provided to participants during their study participation.
Participating in clinical research may offer the opportunity to take a more active role in your healthcare, potentially access an investigational medication, and help advance research that may benefit others in the future.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this study. This does not mean you will not qualify for different research studies.
This research study is evaluating an investigational medication for IgA nephropathy (IgAN) in adults. You may be able to take part in this study if you:
Study participation will last up to 110 weeks and includes up to 26 visits. This includes a 22-week treatment period followed by an 82-week follow-up period. Those who qualify will be randomly assigned (like flipping a coin) to receive either the investigational medication (called mezagitamab) or a placebo (a substance that looks like the investigational medication but contains no active ingredients), along with standard-of-care therapy. Two out of every 3 participants will receive the investigational medication, and 1 out of 3 will receive the placebo.
During the 22-week treatment period, participants will receive subcutaneous (under the skin) injections for a total of 16 doses. Participants will then enter an 82-week follow-up period.
Participation can last up to 110 weeks and includes up to 26 visits.
The investigational medication is a compound that aims to slow down the progression of IgAN by reducing how much of the defective IgA protein is produced in the body. It will be given as a subcutaneous (under the skin) injection.
Do not discontinue any medication unless you are advised to do so by the study staff or your primary care provider.
Travel-related support for this study may be available depending on country and site regulatory approvals. The investigational medication, placebo, and all study-related tests will be provided to participants during their study participation.
Participating in clinical research may offer the opportunity to take a more active role in your healthcare, potentially access an investigational medication, and help advance research that may benefit others in the future.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this study. This does not mean you will not qualify for different research studies.
You are now leaving www.amigastudy.com and being redirected to a website that is not operated by Clinical Trial Media Inc.
